Rick E. Winningham - 28 Feb 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: TBPH
Reported as of: 28 Feb 2025
Net transaction value: +$20,364
SEC form: 4
Accepted by SEC: 04 Mar 2025, 18:17:21 UTC
Prior SEC filing: 24 Feb 2025
Next SEC filing: 22 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Rick E. Winningham filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 04 Mar 2025.

Key facts

This page summarizes Rick E. Winningham's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Mar 2025, 18:17.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: +$20,364.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Award

Transaction value: $20,364
Shares: +2,178
Change %: +0.12%
Price: $9.35
Shares after: 1,778,144
Date: 28 Feb 2025
Ownership: Direct
Footnotes: F1

TBPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,900
Date: 28 Feb 2025
Ownership: As Custodian

TBPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 92,567
Date: 28 Feb 2025
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on February 28, 2025.